- XtalPi Holdings announced in October 2026 that it had selected its first internally developed siRNA preclinical candidate for IgA nephropathy, using its Kodexia platform to jointly design RNA sequence and chemistry for high potency, durability, and a broad safety window in preclinical models.
- The program finished in nine months and reported subnanomolar silencing potency with multi month protein suppression in non-human primates, highlighting how XtalPi’s closed-loop AI and automated experimentation workflow may compress timelines and reshape its future drug discovery cost and productivity profile.
- Attention now turns to how XtalPi Holdings’ investment narrative could shift as investors weigh Kodexia’s rapid siRNA progress in the context of long development timelines.
Scan beyond XtalPi Holdings and this IgA nephropathy update by reviewing a curated set of AI-driven drug discovery players in our 38 profitable AI stocks that aren't just burning cash.
What Is XtalPi Holdings' Investment Narrative?
XtalPi Holdings asks you to believe in a high fixed cost, high potential payoff model. The core bet is that Kodexia and the broader AI for Science tools turn heavy R&D spend into a scalable drug discovery and services engine. The IgA nephropathy siRNA nomination goes straight to that question. It shows the platform can move from software into proprietary therapeutics, but it also pulls the business deeper into long, expensive development cycles where cash burn and execution discipline matter more than any single headline.
In the short term, the share price has fallen about 46% over the past year while revenue still sits at HK$679.2m and the group remains loss making, with a HK$210.9m net loss and a 33.3x P/S multiple. That sets a tightrope. Investors are watching whether management can keep growing AI driven solutions and partnerships while funding capital intensive pipeline work like this siRNA asset without frequent dilution or overreliance on higher risk borrowing.
Even so, there is a specific pressure point in this story that could change how you read all of those numbers.
There's only one way to know the right time to buy, sell or hold XtalPi Holdings. Head to Simply Wall St's company report for the latest analysis of XtalPi Holdings's Fair Value.
Exploring Other Perspectives
The Simply Wall St Community offers only two fair value views for XtalPi Holdings, yet they stretch from 0.56x to 9.93x the current price, underscoring how far opinions can spread. Those figures were set before the siRNA announcement. You now face an open question: revisit these contrasting estimates and weigh several alternative viewpoints.
Explore another XtalPi Holdings fair value estimate, including one that suggests as much as 91% downside from the current price.
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your XtalPi Holdings research is our analysis highlighting 1 key reward that could impact your investment decision.
- See our latest analysis for XtalPi Holdings. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate XtalPi Holdings' overall financial health at a glance.
Looking For More Investment Ideas Beyond XtalPi Holdings?
Once you have formed a view on XtalPi Holdings, it can help to compare that thesis against other businesses that offer different mixes of quality, risk, and income. The Simply Wall St Screener gives you a way to widen your watchlist without losing focus on the factors that matter most to you.
- If you care most about quality at a reasonable entry point, take a look at a 191 high quality undervalued stocks that may line up with your own margin of safety preferences.
- If capital preservation and steadier profiles are higher on your list, consider companies drawn from a 228 resilient stocks with low risk scores that score well on resilience.
- If you want to go beyond well known tickers, scan through a 609 high quality undiscovered gems that combine strong fundamentals with lower market attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com